These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8942000)

  • 1. Plasma concentration and acute clinical effects of docarpamine, orally active dopamine prodrug, in infants.
    Tomita H; Fuse S; Chiba S
    Acta Paediatr Jpn; 1996 Oct; 38(5):440-3. PubMed ID: 8942000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of docarpamine on hemodynamics after open heart surgery in children.
    Watarida S; Shiraishi S; Sugita T; Katsuyama K; Nakajima Y; Yamamoto R; Yamamoto Y; Imura M; Hirokawa R; Mori A
    Ann Thorac Cardiovasc Surg; 2000 Apr; 6(2):106-9. PubMed ID: 10870004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery.
    Tano K; Yoshizumi M; Kitagawa T; Hori T; Kitaichi T; Itoh K; Katoh I
    Life Sci; 1997; 61(15):1469-78. PubMed ID: 9328226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study.
    Funasaki T; Tsutsumi M; Takase S; Tsuchishima M; Ueshima Y; Urashima S; Shimanaka K; Itoh T; Kawahara H
    Am J Gastroenterol; 1999 Sep; 94(9):2475-81. PubMed ID: 10484011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine.
    Tsunoda T; Shibahara H; Hirano Y; Suzuki T; Fujiwara H; Takamizawa S; Ogawa S; Motoyama M; Suzuki M
    Gynecol Endocrinol; 2003 Aug; 17(4):281-6. PubMed ID: 14503971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery.
    Matsubayashi K; Ueda Y; Ogino H; Sugita T; Sakakibara Y; Matsuyama K; Nomoto T
    Thorac Cardiovasc Surg; 1999 Dec; 47(6):352-6. PubMed ID: 10670791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of dopamine prodrug, docarpamine.
    Yoshikawa M; Nishiyama S; Takaiti O
    Hypertens Res; 1995 Jun; 18 Suppl 1():S211-3. PubMed ID: 8529066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs.
    Nishiyama S; Kanno K; Yamaguchi I
    J Pharmacobiodyn; 1991 Mar; 14(3):120-5. PubMed ID: 1679131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats.
    Yamaguchi I; Nishiyama S; Akimoto Y; Yoshikawa M; Nakajima H
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):879-86. PubMed ID: 2484082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiorenal effects of an orally active dopamine prodrug (TA-870) in patients with congestive heart failure.
    Kubota J; Kubo S; Nishimura H; Ueyama M; Kino M; Nakayama A; Hara M; Kawamura K
    J Cardiovasc Pharmacol; 1989 Jul; 14(1):53-7. PubMed ID: 2475715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
    Yoshikawa M; Endo H; Komatsu K; Fujihara M; Takaiti O; Kagoshima T; Umehara M; Ishikawa H
    Drug Metab Dispos; 1990; 18(2):212-7. PubMed ID: 1971575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
    Metra M; Missale C; Spano PF; Cas LD
    J Cardiovasc Pharmacol; 1995 May; 25(5):732-40. PubMed ID: 7630152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel, orally active dopamine prodrug TA-870. V. Natriuretic and positive inotropic effects in rats: an assessment after chronic administration.
    Nishiyama S; Yamaguchi I
    J Cardiovasc Pharmacol; 1991 May; 17(5):768-77. PubMed ID: 1713992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogs.
    Yoshikawa M; Endo H; Komatsu K; Sugawara Y; Takaiti O
    J Pharmacobiodyn; 1990 Apr; 13(4):246-53. PubMed ID: 2384858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of dopamine modulators on the cardiovascular and renal systems.
    Doggrell SA
    Expert Opin Investig Drugs; 2002 May; 11(5):631-44. PubMed ID: 11996645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L; Metra M; Nodari S; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure.
    Nakano T; Morimoto Y; Kakuta Y; Konishi T; Kodera T; Kanamaru M; Takezawa H
    Arzneimittelforschung; 1986 Dec; 36(12):1829-34. PubMed ID: 3551968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
    Lieverse AG; Girbes AR; Van Veldhuisen DJ; Smit AJ; Zijlstra JG; Meijer S; Lie KI; Reitsma WD
    Eur Heart J; 1995 Jul; 16(7):937-42. PubMed ID: 7498209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
    Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
    Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical efficacy of oral dopaminergic agents: new findings].
    Dei Cas L; Metra M; Nodari S; Raccagni D
    Cardiologia; 1995 Dec; 40(12 Suppl 1):131-8. PubMed ID: 8998705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.